Burkina Faso vs Dominican Republic: Antiretroviral therapy coverage for PMTCT
Burkina Faso
69.0%
in 2024
Dominican Republic
68.0%
in 2024
Burkina Faso rank
52nd
Dominican Republic rank
54th
Antiretroviral therapy coverage for PMTCT over time
- Burkina Faso
- Dominican Republic
How they compare
Burkina Faso currently reports 69.0% against 68.0% in Dominican Republic, a difference of 1.0%.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Dominican Republic ahead.
Burkina Faso ranks 52nd and Dominican Republic ranks 54th of 84 countries.
Across the 3 decades both report, Burkina Faso averaged higher in 2 and Dominican Republic in 1.
Head to head by decade
| Decade | Burkina Faso | Dominican Republic | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 10.0% | 16.8% | 6.8% | Dominican Republic |
| 2010s | 51.5% | 37.7% | 13.8% | Burkina Faso |
| 2020s | 79.8% | 49.8% | 30.0% | Burkina Faso |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage for pmtct, Burkina Faso or Dominican Republic?
- Burkina Faso, at 69.0% against 68.0% in Dominican Republic as of 2024.
- What is the difference in antiretroviral therapy coverage for pmtct between Burkina Faso and Dominican Republic?
- 1.0%, with Burkina Faso ahead.
- How many years of comparable data are there for Burkina Faso and Dominican Republic?
- 25 years are reported by both, from 2000 to 2024.
- How do Burkina Faso and Dominican Republic rank globally for antiretroviral therapy coverage for pmtct?
- Burkina Faso ranks 52nd and Dominican Republic ranks 54th of 84 countries.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).